Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-145
Official listed status: posted
Closing information: 2028-01-07 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Independent school districts; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; County governments; Special district governments; Public housing authorities/Indian housing authorities; Native American tribal organizations (other than Federally recognized tribal governments); City or township governments; Private institutions of higher education; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); State governments
Federal synopsis
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.